PROGRESSIVE PULMONARY FIBROSIS: THERAPEUTIC AND DIAGNOSTIC TACTICS AND A SINGLE TARGET DRUG
Summary. The scientific and practical conference with international participation «Ukrainian Rheumatology Forum-2022», which was held by the Ukrainian Association of Rheumatologists last October in Kyiv, was remembered for its interesting reports and great interest from numerous participants. One of the latest concepts discussed during the event is the early detection, monitoring and treatment of interstitial lung disease (ILD) — a severe complication of almost all rheumatic diseases of autoimmune origin. An innovative drug specifically designed to slow down the ever-progressing self-sustaining fibrotic process in ILD is the recently approved for use according to the relevant indication OFEV®/VARGATEF® (nintedanib) from the company «Boehringer Ingelheim International GmbH» (Germany).
Leave a comment